Boehringer Ingelheim Fremont, Inc.
6701 Kaiser Drive
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim Fremont, Inc. is part of Boehringer Ingelheim Biopharmaceuticals GmbH, a leading biopharmaceutical contract manufacturer, known under the brand name Boehringer Ingelheim BioXcellence™. As a mammalian cell culture center in the heart of Silicon Valley, more than 600 scientists and specialists are committed to research, development and manufacturing to make high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and continuous manufacturing. With the complete range of services, from cell line and strain development including high expression systems through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality. Boehringer Ingelheim Biopharmaceuticals GmbH has over 35 years of biotechnology experience, more than 4,600 dedicated and highly trained employees. With our global network, we have helped customers to bring more than 35 molecules to the market. Our network of facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China for manufacturing in mammalian cell culture and microorganisms. We are one integrated global team with one shared passion: Your product.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
950 articles with Boehringer Ingelheim Fremont, Inc.
Another potential treatment for Alzheimer's disease has been tossed into the rubbish bin.
Merial, Now Part of Boehringer Ingelheim, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK Oral Bordetella
RECOMBITEK vaccines are manufactured by Merial. Merial is now a part of Boehringer Ingelheim.
Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.
Boehringer Ingelheim announced today that Paul Fonteyne, U.S. President and CEO will retire after 15 years of committed service on December 31, 2018.
As a PBM owned by 18 Blue Cross and Blue Shield plans, Prime is uniquely positioned to analyze both medical and pharmacy claims data to evaluate and manage total cost of care.
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
The study examined major bleeding and stroke rates in NVAF patients who had initiated treatment with Pradaxa compared to those treated with rivaroxaban or apixaban.
Boehringer Ingelheim Release: Respimat Inhaler Awarded Arthritis Foundation’s Ease of Use Commendation
Boehringer Ingelheim announced today that the Arthritis Foundation recognized Respimat with its Ease of Use Commendation.
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
Tislelizumab will be manufactured in Boehringer Ingelheim’s world-class biopharmaceutical manufacturing facility in Shanghai.
The additional funds will be used to invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others.
Boehringer Ingelheim Release: New Documentary Film Shines Light on Physical and Emotional Impact of COPD
The film was created by Emmy-nominated director Abbey LeVine in collaboration with Boehringer Ingelheim Pharmaceuticals.
The collaboration is part of Boehringer Ingelheim's RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.
Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients.
Under terms of the deal, Boehringer has the option to acquire Autifony's Kv3.1/3.2 positive modulator platform, which includes the company's lead compound AUT00206.
Boehringer's global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
Boehringer Ingelheim Release: FDA Grants Priority Review To Gilotrif For Uncommon EGFR Mutations In Advanced NSCLC
Anthem, HealthCore And Boehringer Ingelheim Initiate World’s Largest Pragmatic Clinical Trial To Study People Living With COPD In A Real-World Setting
Siamab And Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration To Develop Antibody Therapeutics Targeting Multiple Solid Tumors
Boehringer Ingelheim Partners With Greatergood.Org; Provides Over Half A Million Dollars In Product Aid To Pets Affected By Hurricanes Harvey And Irma
ImaginAb, Inc. Announces Strategic Collaboration With Boehringer Ingelheim To Develop New Technology For Monitoring Anti-Tumor Activity Of The Immune System
Geisinger And Boehringer Ingelheim Collaborate To Create A Predictive Model To Help Improve Health Outcomes For People With Type 2 Diabetes At Greatest Risk Of Serious Long-Term Complications, Including Cardiovascular Death